BRPI0913109B8 - solução aquosa oftálmica - Google Patents

solução aquosa oftálmica

Info

Publication number
BRPI0913109B8
BRPI0913109B8 BRPI0913109A BRPI0913109A BRPI0913109B8 BR PI0913109 B8 BRPI0913109 B8 BR PI0913109B8 BR PI0913109 A BRPI0913109 A BR PI0913109A BR PI0913109 A BRPI0913109 A BR PI0913109A BR PI0913109 B8 BRPI0913109 B8 BR PI0913109B8
Authority
BR
Brazil
Prior art keywords
pgf2
analogues
alpha
aqueous solution
aqueous
Prior art date
Application number
BRPI0913109A
Other languages
English (en)
Inventor
Lehmussaari Kari
Oksala Olli
Pellinen Pertti
Reunamaki Timo
Original Assignee
Agc Inc
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0913109(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agc Inc, Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Agc Inc
Publication of BRPI0913109A2 publication Critical patent/BRPI0913109A2/pt
Publication of BRPI0913109B1 publication Critical patent/BRPI0913109B1/pt
Publication of BRPI0913109B8 publication Critical patent/BRPI0913109B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

solução aquosa oftálmica, uso de análogos de pgf2(alfa), e, método para aumentar a solubilidade em água e melhorar a estabilidade de análogos de pgf2(alfa) em uma solução aquosa oftálmica. a presente invenção refere-se a uma composição aquosa oftálmica que contém análogos de pgf2(alfa) para o tratamento de hipertensão ocular e de glaucoma, a um método para o tratamento de hipertensão ocular e de glaucoma por administração da dita composição a um sujeito que necessite tal tratamento e a um método para aumentar a solubilidade em água e a estabilidade de análogos de pgf2(alfa) em uma composição aquosa.
BRPI0913109A 2008-05-30 2009-05-28 solução aquosa oftálmica BRPI0913109B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma
PCT/JP2009/060211 WO2009145356A1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Publications (3)

Publication Number Publication Date
BRPI0913109A2 BRPI0913109A2 (pt) 2017-06-20
BRPI0913109B1 BRPI0913109B1 (pt) 2019-10-22
BRPI0913109B8 true BRPI0913109B8 (pt) 2021-05-25

Family

ID=39940592

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913109A BRPI0913109B8 (pt) 2008-05-30 2009-05-28 solução aquosa oftálmica

Country Status (27)

Country Link
US (3) US9999593B2 (pt)
EP (8) EP2127638A1 (pt)
JP (9) JP2011521943A (pt)
KR (5) KR101820816B1 (pt)
CN (1) CN102083413B (pt)
AR (2) AR071937A1 (pt)
AU (1) AU2009252210C1 (pt)
BR (1) BRPI0913109B8 (pt)
CA (2) CA2724194C (pt)
CY (2) CY1115565T1 (pt)
DK (4) DK2772249T3 (pt)
EA (1) EA023661B1 (pt)
ES (6) ES2495316T3 (pt)
GE (1) GEP20156220B (pt)
HR (4) HRP20220361T1 (pt)
HU (3) HUE033103T2 (pt)
JO (1) JO3039B1 (pt)
LT (3) LT3714877T (pt)
MX (1) MX2010012987A (pt)
MY (1) MY159463A (pt)
PL (4) PL3205334T3 (pt)
PT (4) PT3714877T (pt)
SG (1) SG191628A1 (pt)
SI (4) SI2772249T1 (pt)
TW (1) TWI432202B (pt)
UA (1) UA102257C2 (pt)
WO (1) WO2009145356A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US10154923B2 (en) * 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
CA2806973A1 (en) * 2010-07-29 2012-02-02 Allergan, Inc. Preservative free bimatoprost solutions
US9078854B2 (en) * 2010-07-29 2015-07-14 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
ES2616089T3 (es) * 2010-09-21 2017-06-09 S & V Technologies Gmbh Composición cosmética
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
PL2887923T3 (pl) * 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9913849B2 (en) 2014-01-10 2018-03-13 Manistee Partners Llc Treatment of migraines
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
PL3103439T3 (pl) 2015-06-09 2019-12-31 Medproject Pharma-Entwicklungs- Und Vertriebsgesellschaft Mbh Zdolny do tworzenia kropli oftalmiczny żel bimatoprostu
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
JP2018533629A (ja) * 2015-11-06 2018-11-15 アキュイティス ファーマシューティカルズ、インコーポレイテッド 眼障害を治療するためのプロテアソーム阻害剤の使用
EP3373976B1 (en) 2015-11-10 2024-01-03 Sun Pharmaceutical Industries Limited Topical formulations and uses thereof
US10918694B2 (en) 2016-02-29 2021-02-16 Sun Pharma Global Fze Topical cyclosporine-containing formulations and uses thereof
GR1009040B (el) * 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
ES2972844T3 (es) * 2017-03-27 2024-06-17 Alcon Inc Preparación farmacéutica
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
KR102115285B1 (ko) 2017-06-22 2020-05-26 연성정밀화학(주) 녹내장 치료용 점안 조성물
CA3086457A1 (en) * 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
EA202190214A1 (ru) 2018-07-09 2021-04-16 Варшавске Закляды Фармацеутычне Польфа Са Офтальмологическое дозирующее устройство
JP7599838B2 (ja) * 2019-04-10 2024-12-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性医薬組成物
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
CN116687842A (zh) * 2022-02-28 2023-09-05 山东新时代药业有限公司 一种拉坦前列素滴眼液及其制备方法
WO2023182480A1 (ja) * 2022-03-25 2023-09-28 株式会社坪田ラボ 水性組成物
CN119384280A (zh) * 2022-06-16 2025-01-28 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
JPWO2024203727A1 (pt) * 2023-03-24 2024-10-03
CN121057582A (zh) * 2023-05-11 2025-12-02 特一华制药株式会社 抑制了前列腺素F2α衍生物的含有率降低的产品
JP7757564B1 (ja) 2024-06-28 2025-10-21 東亜薬品株式会社 水性組成物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
DE3871596T3 (de) 1987-04-03 2000-09-07 Pharmacia & Upjohn Ab, Stockholm Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes.
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
EP1057486A1 (en) * 1995-11-17 2000-12-06 Alcon Laboratories, Inc. Use of drug combination for treating Glaucoma
ATE221048T1 (de) 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
CA2273837C (en) 1996-12-09 2003-12-30 Bausch & Lomb Incorporated Single-use flexible container
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
ATE326972T1 (de) 1997-10-13 2006-06-15 R Tech Ueno Ltd Heilende zusammensetzung für intraokulare hypertension oder glaukom
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
WO2000003736A1 (en) 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Prostaglandin product
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US6486208B1 (en) 1998-09-25 2002-11-26 Alcon Laboratories, Inc. Sustained release, and comfortable opthalmic composition and method for ocular therapy
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
DE60039132D1 (de) 1999-04-06 2008-07-17 Sepracor Inc O-Desmethylvenlafaxin-Succinat
ATE324910T1 (de) 2000-06-19 2006-06-15 Santen Pharmaceutical Co Ltd Aseptische mittel
CA2422031C (en) 2000-09-13 2011-11-15 Santen Pharmaceutical Co., Ltd. Ophthalmic solutions comprising difluoroprostaglandin f2 alpha
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
TW586946B (en) 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
WO2004006826A1 (ja) 2002-07-16 2004-01-22 Senju Pharmaceutical Co., Ltd. 薬液容器及びその製造方法
CA2707067C (en) 2002-09-09 2013-07-16 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
WO2005011704A1 (ja) 2003-07-31 2005-02-10 Santen Pharmaceutical Co., Ltd. プロスタグランジン含有製品
US20050287325A1 (en) 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
DE602004017477D1 (de) 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
WO2006058139A2 (en) 2004-11-24 2006-06-01 Holopack International Corp. Dispensing container with flow control system
CN102526064A (zh) 2004-12-09 2012-07-04 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
WO2006068266A1 (ja) 2004-12-24 2006-06-29 Santen Pharmaceutical Co., Ltd. プロスタグランジンＦ２ａ誘導体含有製品
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
CA2615108A1 (en) 2005-07-13 2007-01-18 Santen Pharmaceutical Co., Ltd. Preservative composition for ophthalmic use
EP1916002B1 (en) 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
PT1937212E (pt) 2005-10-10 2010-11-30 Novagali Pharma Sa Emulsões oftálmicas contendo prostaglandinas
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
JP2024079852A (ja) 2024-06-11
JP7265584B2 (ja) 2023-04-26
HUE033103T2 (en) 2017-11-28
DK3205334T3 (da) 2020-07-13
EP2772249B1 (en) 2017-05-03
EP4512424A2 (en) 2025-02-26
JP7520285B2 (ja) 2024-07-23
BRPI0913109B1 (pt) 2019-10-22
EP3205334B1 (en) 2020-04-29
DK2306977T3 (da) 2014-09-15
KR20110011707A (ko) 2011-02-08
MY159463A (en) 2017-01-13
KR20200057801A (ko) 2020-05-26
AU2009252210B2 (en) 2014-10-16
PT2306977E (pt) 2014-09-22
CY1120351T1 (el) 2019-07-10
CY1115565T1 (el) 2017-01-04
JP2014133765A (ja) 2014-07-24
KR20180008905A (ko) 2018-01-24
SI2772249T1 (sl) 2017-08-31
EP4512424A3 (en) 2025-03-05
JP2011521943A (ja) 2011-07-28
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
HRP20140979T1 (hr) 2014-11-21
HUE058079T2 (hu) 2022-06-28
AU2009252210C1 (en) 2016-04-14
PL2772249T3 (pl) 2017-10-31
ES2968837T3 (es) 2024-05-14
KR101820816B1 (ko) 2018-01-22
PT3205334T (pt) 2020-07-31
JP2018154656A (ja) 2018-10-04
US10864159B2 (en) 2020-12-15
US20180289618A1 (en) 2018-10-11
DK3714877T3 (da) 2022-02-14
US9999593B2 (en) 2018-06-19
SG191628A1 (en) 2013-07-31
JP6649992B2 (ja) 2020-02-19
TWI432202B (zh) 2014-04-01
CA2724194C (en) 2017-06-27
ES2907982T3 (es) 2022-04-27
HRP20220361T1 (hr) 2022-05-13
CA2724194A1 (en) 2009-12-03
JP2020073574A (ja) 2020-05-14
AR120961A2 (es) 2022-04-06
US20110152264A1 (en) 2011-06-23
WO2009145356A1 (en) 2009-12-03
ES2495316T3 (es) 2014-09-17
EP2306977B1 (en) 2014-08-13
DK2772249T3 (en) 2017-07-17
KR101988642B1 (ko) 2019-06-12
US20210059931A1 (en) 2021-03-04
EP4035656A1 (en) 2022-08-03
AU2009252210A1 (en) 2009-12-03
EP4289446A3 (en) 2024-01-10
EP3205334A1 (en) 2017-08-16
LT3714877T (lt) 2022-04-11
HRP20170769T1 (hr) 2017-08-11
ES2808050T3 (es) 2021-02-25
KR20160102319A (ko) 2016-08-29
AR071937A1 (es) 2010-07-28
JP2023085558A (ja) 2023-06-20
ES3014089T3 (en) 2025-04-16
EP4289446B1 (en) 2025-02-12
ES2627837T8 (es) 2018-02-26
EP4289446A2 (en) 2023-12-13
JO3039B1 (ar) 2016-09-05
PL3714877T3 (pl) 2022-05-16
EP2306977A1 (en) 2011-04-13
CN102083413B (zh) 2013-11-06
EP2127638A1 (en) 2009-12-02
JP2017178957A (ja) 2017-10-05
EP4512424B1 (en) 2026-03-18
JP6148317B2 (ja) 2017-06-14
GEP20156220B (en) 2015-01-26
PT3714877T (pt) 2022-03-10
HUE049923T2 (hu) 2020-11-30
JP2021120412A (ja) 2021-08-19
PL3205334T3 (pl) 2020-11-02
EP3714877A1 (en) 2020-09-30
EA023661B1 (ru) 2016-06-30
UA102257C2 (uk) 2013-06-25
KR102114401B1 (ko) 2020-05-25
PT2772249T (pt) 2017-08-08
ES2627837T3 (es) 2017-07-31
JP6889789B2 (ja) 2021-06-18
EA201071413A1 (ru) 2011-06-30
PL2306977T3 (pl) 2015-01-30
CN102083413A (zh) 2011-06-01
JP6356868B2 (ja) 2018-07-11
KR20190067272A (ko) 2019-06-14
LT3205334T (lt) 2020-09-25
EP3714877B1 (en) 2022-01-26
KR102246598B1 (ko) 2021-04-30
EP2772249A1 (en) 2014-09-03
KR101650006B1 (ko) 2016-08-22
JP2016065095A (ja) 2016-04-28
TW201000104A (en) 2010-01-01
MX2010012987A (es) 2011-02-24
CA2965185A1 (en) 2009-12-03
SI3714877T1 (sl) 2022-05-31
BRPI0913109A2 (pt) 2017-06-20
HRP20200998T1 (hr) 2020-10-16
EP4035656B1 (en) 2023-11-22
LT2772249T (lt) 2017-09-11

Similar Documents

Publication Publication Date Title
BRPI0913109B8 (pt) solução aquosa oftálmica
BR112014005700A2 (pt) composições oftálmicas compreendendo derivados de prostaglandina f2 alfa e ácido hialurônico
MX2016005574A (es) Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
MX2010007295A (es) Composiciones acuosas estables de ciclosporina.
MX341684B (es) Composicion para el uso en la prevencion y/o tratamiento de condiciones de la piel y enfermedades de la piel.
BR112015001313A2 (pt) composições de vacina
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
BR112013022057A2 (pt) composição oftálmica de olopatadina de alta concentração
BRPI0924653B8 (pt) composto de ferro-oligossacarídeo, composição e uso de deste composto
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
UY32848A (es) Compuestos heterocíclicos de oxima
CR20120264A (es) Compuestos
BRPI0907970A8 (pt) composição para tratamento dos cabelos ou pelos e método para aumentar o diâmetro dos cabelos ou pelos
MX2016012933A (es) Composiciones de relleno de tejidos y metodos de uso.
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
UA107562C2 (uk) Спосіб лікування псоріазу
BR112012028437A2 (pt) solução oftálmica, e, método para tratar glaucoma ou hipertensão ocular
ES2517491T3 (es) Estabilizador de los vasos linfáticos
UY32131A (es) Compuestos de anillo fusionado y uso de los mismos
CL2011001026A1 (es) Uso de pimobedan para preparar un medicamento util en el tratamiento de cardiomiopatia hipertrofica en un gato.
BR112013022414A2 (pt) método para melhorar a rejeição de membrana permeável, agente de tratamento para melhorar a rejeição e membrana permeável
MX350392B (es) Aceite de sandalo y sus usos.
BR112012027393A2 (pt) composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SANTEN PHARMACEUTICAL CO., LTD. (JP) ; AGC INC. (J

B25G Requested change of headquarter approved

Owner name: SANTEN PHARMACEUTICAL CO., LTD. (JP) ; AGC INC. (JP)

Owner name: SANTEN PHARMACEUTICAL CO., LTD. (JP) ; AGC INC. (J

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/10/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2829 DE 25-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.